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modalities and strongly suggest durability of our results. Further 
follow up is needed to confirm this.  
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Purpose/Objective: To update a Hypofractionated Tomotherapy 
Treatment (HTT) feasibility-study, by evaluation of toxicity and 
outcome, in lymph nodal relapse of patients (pts) already treated for 
prostate cancer. The role of 11CCholine PET/CT in detecting prostate 
cancer recurrence and as a 'guide' for Tomotherapy treatment was 
also evaluated. 
Materials and Methods: From January 2005 to August 2012, 49 
prostate cancer pts with biochemical recurrence and evidence of 
lymph nodal relapse at 11CCholine PET/CT scan (PET/CT0) were 
treated with moderately hypofractionated Tomotherapy. All pts had 
undergone previous prostatectomy, radical radiation therapy (RT) or 
prostatectomy + RT and all were currently receiving systemic therapy. 
One patient was treated 3 times, two patients twice: the total 
number of therapies was 53. In 49/53 cases PET/CT0 detected 
metastases (LNMs) at para-aortic and/or pelvic level, in 4 cases at the 
mediastinal level. Pelvic and/or lombo-aortic lymph nodes were 
treated to 51.8Gy/28 fractions and PET/CT0 positive lymph nodes 
were treated with higher dose using a simultaneous integrated boost. 
A Mega-Voltage CT scan (MVCT) was performed before each fraction 
to allow correct patient repositioning in order to reduce PTV margin 
and side effects to surrounding tissues. The doses ranged from 42 Gy 
in 6 fractions to 74.2 Gy in 28 fractions. To evaluate treatment 
efficacy, PSA serum measurement (PSA1) (all pts) and 11CCholine 
PET/CT(PET/CT1) (n=19) were performed after treatment and 
compared to basal evaluations. 
Results: In 17/49 pts (53 therapies) 6 genito-urinary [GU] and 11 
upper-gastro intestinal [uGE] G1 acute toxicities were recorded. Only 
5 G2 uGE and 2 G2 GU were observed. 3 pts had G1 rectum toxicity 
and 3 pts G1 erythema. No G3-G4 acute side effects were registered. 
Among the 41 pts with follow-up longer than 3 months, 5 had G1 late 
toxicity (1uGE and 4GU), 3 presented G2GU toxicity, one G2 rectal 
toxicity and 3 G3 GU toxicity. With a median follow-up of 24 months 
(range: 0-88)37/41 pts had a significant reduction of PSA value after 
HTT. Of the 19 pts with PET/CT1 evaluation, 14 had Complete 
Metabolic Response and 2 Partial Metabolic Response. During follow-
up, only 3 of the 41 evaluable pts had progression in the irradiated 
area and 7 in other sites. One died of tumour progression. Half of the 
patients in complete remission maintained good PSA control even 
after suspending their medical treatment. Mean Overall survival was 
31.73 months; Overall Survival at 36 months was 85.7%, PFS at 36 
months was 32.8%. 
Conclusions: These preliminary data show that HTT 11CCholine 
PET/CT-guided with IGRT for precise repositioning is safe and 
effective in lymph nodal relapse of prostate cancer pts and could be a 
valid alternative to chemotherapy. Although further evaluations are 
necessary, the good rate of local control suggests that HTT treatment 
guided by 11CCholine PET/CT images maybe reasonably proposed in 
these patients. 
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Purpose/Objective: International Prostate Symptoms Score (IPSS) at 
baseline and at one year follow-up were compared in Active 
Surveillance (AS) vs radical radiation (RT) pts. Aim of the present 
analysis was to determine if the expected changes in IPSS after RT has 
also psychological distress or age-related components in addition to 
radio-induced bladder/urethral toxicity. 
Materials and Methods: Between Dec 09 and Jul 12, 211 RT pts 
completed IPSS at baseline (T0) and 86/211 at one year from RT end 
(T1). Between Nov 07 and Nov 12, 145 AS pts completed the IPSS 
questionnaire at T0 and 57/145 at one year from AS enrolment (T1). 
IPSS was divided into 5 groups: =0 (no symptoms, symp), 1-7 (mild 
symp), 8-14 (mild to moderate symp), 15-19 (moderate symp) and 20-
35 (severe symp). Possible associations between clinical variables and 
IPSS were determined through Pearson correlation coefficient. 
Clinically significant changes over time were defined as at least 4, 6, 
8 IPSS increase, defined as mild, moderate and severe worsening, 
respectively. Z-test for proportions was used to investigate 
statistically significant differences in % of pts with mild to severe GU 
symp worsening in the two cohorts (AS vs RT). 
Results: Mean age: 65 vs 70 in AS and RT. Mean initial PSA: 5.1 vs 12.8 
ng/ml, AS vs RT. AS pts were all ≤low-risk; RT pts: 26% low, 41.5% 
intermediate and 32.5% high-risk. Figure 1 shows the distribution of 
IPSS classes at T0 stratified by age and cohort. Youngest RT pts 
reported the best IPSS, while AS pts >70yrs showed the highest rate 
(24%) of moderate/severe symp. 
No significant correlation was found for age, clinical stage, initial PSA 
and BMI.  35% vs 21% pts (in AS and RT respectively, p=0.06) reported 
at least 4-point IPSS worsening, 24% vs 15% (p=0.16) and 12% vs 9% 
(p=0.58) at least 6 and 8-point increase, respectively. AS pts with IPSS 
at 2 yr follow-up (T2) showed that 86% of pts with 4-point worsening 
at T1 completely recovered to T0 level (90% and 83% for 6 and 8-
point). 
  
Conclusions: Our prostate cancer RT population reported less GU 
symp (as measured by IPSS) at T0 with respect to the AS population. % 
of pts with mild to severe GU symp worsening after 1 yr follow-up was 
higher in AS, but differences were not statistically significant.  It has 
to be underlined that T1 AS IPSS measurement was performed one 
month after prostate re-biopsy (as established by AS protocol) and 
worsening of GU symp can be caused by biopsy-related acute toxicity. 
This hypothesis is confirmed if AS IPSS at 2 yrs is considered: 85-90% of 
pts recovered to T0 IPSS level. With respect to RT IPSS scores, the use 
of neo-adjuvant hormone therapy (40% of pts) could explain both T0 
and T1 better IPSS in this cohort. Psychological distress or age-related 
components do not seem to play a significant role in GU function 
worsening at 1 yr in RT cohort. Longer follow-up is needed to 
determine the true impact of these variables on late GU radio-induced 
changes. 
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Purpose/Objective: An advantage for the use of carbogen and 
nicotinamide to overcome tumour hypoxia during radiotherapy (RT) 
has been demonstrated for bladder and head and neck cancers (1, 2). 
The aims of this trial are: (1) to evaluate the safety of applying this 
treatment strategy to patients receiving RT for high risk prostate 
cancer; (2) to establish the biochemical progression free survival in 
patients treated with hypoxia modification and (3) to study the 
changes in the tumour micro-environment using multi-parametric 
magnetic resonance (MR) imaging at different time points during the 
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course of their RT. Here we report the acute toxicity outcomes for the 
phase 1b cohort of patients in this trial. 
Materials and Methods: Six patients with high risk prostate cancer 
(PSA>20 or T3a/T3b or Gleason score ≥ 8) were recruited from Jan 
2012 to April 2012. Prior to the start of RT they had all received a 
minimum of three months of LHRH analogue based androgen 
deprivation treatment. RT was delivered using intensity modulated 
techniques to the whole prostate (74Gy in 37fractions) and pelvic 
lymph nodes (60Gy in 37fractions). Patients took nicotinamide tablets 
(60mg/kg) one hour before RT was given, and breathed carbogen gas 
(98% oxygen; 2% carbon dioxide) via a tight fitting mask 10 minutes 
before and during the delivery of RT. Gastrointestinal and urinary 
toxicities were prospectively recorded before RT, at 3, and 6 months 
from the end of RT, and will continue to be monitored on a 6 monthly 
basis until patients have been followed up for a total of five years. 
Toxicities were graded using CTCAE version 4.0. 
Results: All 6 patients completed their treatments according to 
protocol. The mean time between the start of neoadjuvant hormone 
treatment and RT was 121 days. They have all been followed up for a 
minimum of 3 months from the end of their RT. No grade 3 gastro-
intestinal or urinary toxicity has been observed so far. Toxicity (table 
1) in this population group is comparable with those seen during 
standard radiotherapy. 
Conclusions: The addition of carbogen and nicotinamide to standard 
radiotherapy to the prostate and whole pelvis is well tolerated by all 
patients. No practical difficulty related to the administration of 
carbogen during RT was encountered. Recruitment into the phase II 
part of this trial continues. 
 
Table 1 – prevalence of acute urinary or
gastrointestinal toxicity at 3 & 6 months after RT  
CTCAE Grade 1 2 3 
Urinary toxicity 4 (66%) 2 (33%) 0 (0%) 
Gastrointestinal toxicity 3 (50%) 1 (17%) 0 (0%) 
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Purpose/Objective: To evaluate the clinical outcome of a new 
fractionation protocol with transperineal hypofractionated proton 
boost of 20 Gy in daily 5 Gy fractions combined with external beam 
radiotherapy (EBRT) of 50 Gy in daily 2 Gy fractions for patients with 
localized prostate cancer (PC). Assuming a value of a/b of 3 Gy or 1.5 
Gy and a value of relative biological effectiveness (RBE) for protons of 
1.1, the equivalent dose in 2 Gy fractions (EQD2) for this schedule 
would be 87 Gy or 94 Gy respectively. 
Materials and Methods: A cohort of 278 patients treated between 
2002 and 2008 with PC has been followed for a median time of 5 
years. Neoadjuvant androgen deprivation therapy (N-ADT) was given 
to 139 patients. Only 12 patients received pelvic node EBRT. A rectal 
retraction rod was used for 147 patients for better target coverage 
and immobilization. The occurrence of GU toxicities in patients with 
grade 0 and with grade 1 symptoms at baseline were separately 
analysed as they were found as strong predictive factors for 
developing side effects at later times. Both cumulative incidence and 
actuarial prevalence of GU and GI side effects were evaluated 
according to RTOG guidelines. The cohort included 63 low-, 95 
intermediate- and 107 high-risk PC patients with a median follow-up 
time of 5years. 
Results: The 5 and 8 year overall survival of the whole group was 89% 
and 71%. The 5 and 8-year probability for prostate cancer specific 
mortality was 0% for the low- and intermediate groups compared to 7% 
and 17% for the high-risk group, respectively. The 5-year probability 
for PSA relapse was 0%,5% and 26% for low-, intermediate and high-
risk patients, respectively. The 5-year probability for distant 
metastases rate was 0%, 4% and 21% for the low-, intermediate and 
high-risk groups, respectively. Two patients had local failure. 
Evaluating baseline (GU) and (GI) symptoms as well as sexual 
functionbefore treatment was found to be important in the evaluation 
of side effects. Mild pre-treatment GU-symptoms were found to be a 
strong predictive factor for late GU-toxicity. For baseline symptom-
free patients the prevalence at 3 years was 13%, 4%, and 1% for grade 
≥ 2, grade ≥ 3,and grade 4, respectively. Prevalence analysis showed a 
decline in symptoms. At 5 years this group had a prevalence of 1%, 1%, 
and 1% for grade ≥ 2,grade ≥ 3, and grade 4, respectively. No patients 
developed grade 3 or 4 GI toxicities. 
Conclusions: Hypofractionated proton boost combined with EBRT is 
associated with an excellent clinical outcome and low rates of 
treatment toxicities. Bladder toxicities rather than rectal toxicities 
seem to be dose limiting and determined by epithelial damage over 
afollow-up time of 5 years. Long-term follow-up is necessary to 
evaluate the evolvement of any true late progressive and irreversible 
injury. Perineal proton boost preferably with spot scanning may offer 
substantial dose escalation and allow hypofractionation be applied 
safely.  
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Purpose/Objective: To assess the impact of IGRT modality on the risk 
of GR2+ diarrhea during whole pelvis intensity modulated radiotherapy 
for prostate cancer. 
Materials and Methods: 157 consecutive pts were treated at 2 
Institutions (112 pts at Institution A and 45pts at Institution B) in two 
non-overlapping eras under supervision of the same radiation 
oncologist. All pts received prophylactic whole pelvis treatment to 54 
Gy in 30 fxs with either IMRT (Institution A) or VMAT (Institution B). 
Moreover, depending on Institutional policies and availability, daily 
imaging was performed on selected pts with 2 different modalities: 
tracking of 3 seeds in the prostate (translations only) ('fiducials') and 
CBCT+Exactrac aligned to bone (translations + rotations) first and 
eventually to the prostate (translations only) ('CBCT'). In the latter 
subgroup, prostate alignment was based on soft tissues due to the lack 
of fiducials. Diarrhea was prospectively scored during treatment at 
each weekly visit and endpoint is here considered the development of 
GR2+ peak toxicity at any point during treatment according to CTCAE 
v2.0. Based on previous work (Sanguineti et al, Strahlenther Onkol, 
2009), selected covariates (G2+ proctitis, yes vs no, and the absolute 
volume of intestinal cavity receiving at least 15Gy, IC-V15, continuum) 
along with daily imaging technique (no IGRT vs IGRT/fiducialsvs 
IGRT/CBCT) were investigated at logistic regression for their possible 
association with the development of peak GR2+ diarrhea. Moreover, 
within the IGRT/fiducials subgroup, for each pt both the systematic 
(average) and random (SD) errors (mm) along the 3 axes were 
computed and extracted. 
Results: Overall 50 pts (31.8%) developed endpoint. The risk of GR2+ 
diarrhea was 23.5%, 25.0% and 51.1% in pts undergoing no daily IGRT, 
IGRT/CBCT and IGRT/fiducials, respectively (p=0.005). Compared to 
pts treated without daily IGRT (N=68), pts treated with daily 
IGRT/fiducials (N=45) had a OR of 3.4 (95%CI 1.5-7.6, p=0.003) while 
IGRT/CBCT was not associated with an increased risk of GR2+ diarrhea 
(OR=1.1, 95%CI 0.5-2.7, p=0.806). Among pts treated without IGRT or 
with IGRT/CBCT (N=112), G2 proctitis (OR:1.8,95%CI: 1.0-3.0, 
p=0.033) and IC-V15 (OR:1.1, 95%CI: 1.0-1.3, p=0.033) confirmedto be 
predictors of intestinal toxicity. Among pts treated with 
IGRT/fiducials, neither G2 proctitis or IC-V15 predicted endpoint. 
Interestingly, the risk of GR2+ diarrhea was significantly correlated 
with the individual systematic error along craniocaudal (CC) axis (OR: 
1.3, 95% CI 1.0-1.6,p=0.033) and to a lesser extent along 
anteroposterior (AP) axis (OR: 1.2, 95%CI 0.9-1.4, p=0.066). No 
correlation was found with random errors.  
Conclusions: In presence of systematic errors along the CC and/or AP 
axes, tracking the prostate only during WPRT vanishes the role of both 
clinical (proctitis) and dosimetric (V15) factors in predicting the risk 
of diarrhea during treatment. 
   
 
 
 
 
